Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Milleron

Showing results (191-200 of 206) with videos related to

Pageof 21
Sort By:
Clinical Therapeutics|August 25, 2001
The relationship between introduction of American society of clinical oncology guidelines and the use of colony-stimulating factors in clinical practice in a Paris university hospitalI Debrix, P Tilleul, B Milleron, et al.
Revue Des Maladies Respiratoires|February 27, 2021
[Recommendations of French specialists on screening for lung cancer]S Couraud, G Ferretti, B Milleron, et al.
Revue Des Maladies Respiratoires|February 1, 2011
[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]J Tredaniel, F Mornex, I Barillot, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 10, 2005
[Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers]E Deniaud-Alexandre, E Touboul, D Lerouge, et al.
Revue Des Maladies Respiratoires|February 22, 2008
[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]D Moro-Sibilot, F Barlesi, J F Timsit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III studyJ L Pujol, J Y Douillard, A Rivière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancerE Quoix, B Lebeau, A Depierre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 1997
Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue FrançaiseP Jacoulet, A Depierre, D Moro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2005
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatinJ-L Pujol, J-L Breton, R Gervais, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trialB Besse, J Mazières, L Ribassin-Majed, et al.
Pageof 21

Showing results (191-200 of 206) with videos related to

Sort By:
Pageof 21
Clinical Therapeutics|August 25, 2001
The relationship between introduction of American society of clinical oncology guidelines and the use of colony-stimulating factors in clinical practice in a Paris university hospitalI Debrix, P Tilleul, B Milleron, et al.
Revue Des Maladies Respiratoires|February 27, 2021
[Recommendations of French specialists on screening for lung cancer]S Couraud, G Ferretti, B Milleron, et al.
Revue Des Maladies Respiratoires|February 1, 2011
[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]J Tredaniel, F Mornex, I Barillot, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 10, 2005
[Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers]E Deniaud-Alexandre, E Touboul, D Lerouge, et al.
Revue Des Maladies Respiratoires|February 22, 2008
[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]D Moro-Sibilot, F Barlesi, J F Timsit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III studyJ L Pujol, J Y Douillard, A Rivière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancerE Quoix, B Lebeau, A Depierre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 1997
Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue FrançaiseP Jacoulet, A Depierre, D Moro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2005
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatinJ-L Pujol, J-L Breton, R Gervais, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trialB Besse, J Mazières, L Ribassin-Majed, et al.
Pageof 21